Patient-centered outcomes in treatment options for proliferative diabetic retinopathy
摘要
The Diabetic Retinopathy Clinical Research (DRCR) Network Protocol S demonstrated, in a prospective, randomized, multicenter trial, the non-inferiority of intravitreal ranibizumab (IVR) compared to panretinal photocoagulation (PRP) in the treatment of proliferative diabetic retinopathy (PDR) (1).
